secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2023-07-28T23:59:59+00:00
Accession:  0001104659-23-085361
Event type: debt
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acura receives $250K related-party loan; warns may need to terminate operations by end of August 2023
--------------------------------------------------------------------------------

- Received $250K loan from AD Pharma; total note now $3,919,279, matures Dec 31, 2023 at 5.25%.
- AD Pharma holds 66% of common; its managing partner Mr. Schutte directly owns 14%.
- Proceeds cover operations only through August 2023; no assurance of additional financing; may need to scale back or seek bankruptcy.
- Default interest rate 7.5% per annum on overdue amounts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465923085361/0001104659-23-085361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465923085361/tm2322359d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-085361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer